About
News & Events

News

RareCyte® reports significant 2021 growth of Precision Biology Services business and customer uptake of Orion Spatial Biology instruments and reagents

Seattle, WA, January 6th, 2022 - RareCyte Inc., (“RareCyte” or “The Company”) a leading provider of Precision Biology products and services recognized over 100% sales growth in their Services business in 2021. They also saw significant uptake by early adopters of their Orion instruments and consumables by global key opinion leaders in support of fast, subcellular whole slide spatial analysis.

Read more...

RareCyte® Secures $24M Financing to Advance the Orion Spatial Biology Platform and Expand Global Commercial Channels

Seattle, WA, September 9, 2021 – RareCyte, Inc. (“RareCyte” or “the Company”) a Life Sciences company developing and manufacturing proprietary platforms enabling precision biology solutions, announced today the completion of a $24M financing from new and existing investors. The funding will drive the commercialization and applications for the Company’s new Orion spatial biology platform and further global expansion for the Company’s portfolio of instruments and consumables.

Read more...

RareCyte announces new rare cell detection kit for non-epithelial cancers

Seattle, WA, September 7, 2021 – RareCyte® announces a new rare cell detection kit, The Cell Discovery Kit, which enables custom panel development in your lab for the detection of circulating tumor cells (CTCs) that do not express epithelial markers, such as sarcomas and melanoma, as well as other non-tumor rare cell populations. Together with the AccuCyte® Sample Preparation System, the Cell Discovery Kit provides sensitive and specific rare cell identification.

Read more...

RareCyte announces new Synaptophysin CTC assay for blood-based characterization of treatment-resistant malignancies

Seattle, WA, June 01, 2021 – RareCyte® announces a new biomarker liquid biopsy assay for the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer.

Read more...

RareCyte announces first commercially available ARv7/Synaptophysin CTC assay for blood-based characterization of treatment resistant prostate cancer

Seattle, WA, August 26, 2020 – RareCyte® announces a new dual biomarker liquid biopsy assay for androgen receptor splice variant 7 (ARv7) and the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate both ARv7 and SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer.

Read more...

Events

Liquid Biopsy for Precision Oncology
Feb. 10-11, 2022
website →
Visit us in person
United States & Canadian Academy of Pathology
March 19-24, 2022
website →
Visit us in person
TriCon
Feb 21-23, 2022
website →
Visit us in booth #109
AACR
April 8-13, 2022
website →
Visit us in booth #2923